Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
Giovanni MartinottiBernardo Dell'OssoGiorgio Di LorenzoGiuseppe MainaAlessandro BertolinoMassimo ClericiStefano BarlatiGianluca RossoMarco Di NicolaMatteo MarcatiliGiacomo D'AndreaClara CavallottoStefania ChiappiniSergio De FilippisGiuseppe NicolòPasquale De FazioIleana AndriolaRaffaella ZanardiDomenica NuciforaStefania Di MauroRoberta BassettiMauro PettorrusoRoger S McIntyreStefano L SensiMassimo di GiannantonioAntonio Vitanull nullPublished in: Bipolar disorders (2023)
Our results supported the effectiveness and tolerability of esketamine in a real-world population of subjects with B-TRD. The low risk of manic switch in B-TRD patients confirmed the safety of this treatment.
Keyphrases
- bipolar disorder
- randomized controlled trial
- end stage renal disease
- depressive symptoms
- systematic review
- ejection fraction
- newly diagnosed
- chronic kidney disease
- sleep quality
- prognostic factors
- open label
- clinical trial
- big data
- machine learning
- deep learning
- physical activity
- smoking cessation
- double blind
- artificial intelligence
- combination therapy